Intercept Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ICPT)

$59.13 -1.65 (-2.71 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$60.78
Today's Range$59.03 - $61.85
52-Week Range$51.05 - $135.59
Volume670,864 shs
Average Volume1.07 million shs
Market Capitalization$1.54 billion
P/E Ratio-4.19
Dividend YieldN/A
Beta-2.13

About Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals logoIntercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ICPT
CUSIP45845P10
Phone646-747-1000

Debt

Debt-to-Equity Ratio3.15%
Current Ratio5.95%
Quick Ratio5.95%

Price-To-Earnings

Trailing P/E Ratio-4.18971507991661
Forward P/E Ratio-4.49
P/E GrowthN/A

Sales & Book Value

Annual Sales$130.96 million
Price / Sales11.33
Cash FlowN/A
Price / CashN/A
Book Value$12.69 per share
Price / Book4.66

Profitability

Trailing EPS($14.39)
Net Income$-360,370,000.00
Net Margins-275.18%
Return on Equity-207.27%
Return on Assets-58.62%

Miscellaneous

Employees456
Outstanding Shares25,100,000

Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced its earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($4.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.39) by $1.04. The biopharmaceutical company had revenue of $37.69 million for the quarter, compared to analyst estimates of $39.01 million. Intercept Pharmaceuticals had a negative return on equity of 207.27% and a negative net margin of 275.18%. The company's revenue for the quarter was up 173.1% compared to the same quarter last year. During the same quarter last year, the business earned ($4.84) EPS. View Intercept Pharmaceuticals' Earnings History.

When will Intercept Pharmaceuticals make its next earnings announcement?

Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Intercept Pharmaceuticals.

Where is Intercept Pharmaceuticals' stock going? Where will Intercept Pharmaceuticals' stock price be in 2018?

20 Wall Street analysts have issued 1-year target prices for Intercept Pharmaceuticals' shares. Their predictions range from $50.00 to $253.00. On average, they anticipate Intercept Pharmaceuticals' share price to reach $128.37 in the next year. View Analyst Ratings for Intercept Pharmaceuticals.

What are Wall Street analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Intercept’s fourth-quarter results missed expectations as sales of Ocaliva declined due to safety issues surrounding the drug. The approval of Ocaliva was a significant boost for Intercept. However, prescription demand has softened following the Dear Health Care Provider letter and the FDA safety communication on Ocaliva. The company also announced an updated label for Ocaliva in the United States, reinforcing appropriate dosing in PBC patients with Child-P Class B or C or decompensated cirrhosis. While the updated label should help the stock turn around, it might be a while before the sales start to recover. First-quarter is expected to be a transitional quarter. Meanwhile, Intercept is evaluating Ocaliva for other indications including NASH and PSC. Given the challenges faced by the drug in recent times, the label expansion of OCA will boost the growth prospects. Shares have underperformed the industry in the last six months." (2/19/2018)
  • 2. Needham & Company LLC analysts commented, "Intercept reported $40.9M in WW 3Q17 Ocaliva sales, with $4.1M attributed to one-time accounting adjustment. Excluding adjustment, WW and U.S. Ocaliva sales were $36.8M and $32.5M, respectively, both in-line with our and consensus $36M and $33M ests. Company has completed safety review w/ independent committee and discussions w/ FDA are underway. Changes to U.S. label are expected by early 1Q18. Safety concerns appear to have had modest impact on NRX since FDA letter and we have reduced our ests accordingly. Long-term sales in PBC may be negatively impacted by large number of competing programs in development. Maintain HOLD." (11/1/2017)
  • 3. Cantor Fitzgerald analysts commented, "Emerging Safety Risks, but PBC Remains Intact. This morning, Intercept reported results demonstrating 3Q17 revenue growth to $36.8 million (excl. $4.1 million one-time increase in deferred revenue) from $31 million in 2Q17. While the FDA warning letter at the end of the quarter potentially shifts the risk-benefit profile of Ocaliva, an analysis of drug scripts provided by Intercept indicates that the sharp drop in scripts around the time of the news has since abated. Net ex-U.S 3Q17 sales increased to $4.7 million from $2.5 million in 2Q17 during the quarter, largely contributed from Germany and France. No formal guidance for the full-year was given, but management noted that they expect sequential quarterly growth for the balance of 2017. While we do not see a negative impact to our long-run commercialization in PBC, we believe the safety events reaffirm the uncertainty for Ocaliva’s use in NASH (where dosing is higher)." (11/1/2017)
  • 4. Wells Fargo & Co analysts commented, "an increased risk of serious liver injury and death." The letter resulted in a 25 percent selloff in Intercept's stock on Thursday, and some Wall Street analyst's felt it prudent to take action.Wells Fargo's Jim Birchenough downgraded Intercept's stock rating from Overweight to Market Perform with a price target slashed from $265 all the way down to $95 as the letter goes beyond a previous warning.The FDA's letter contains new pieces of information that weren't included in the prior "Dear Healthcare Provider Letter," the analyst highlighted. For example, 19 separate deaths have been identified since Ocaliva's launch in May 2016. The cause of death was worsening primary biliary cholangitis in seven of these cases, cardiovascular disease in one case, with the other cases being unknown.Among the eight cases with a known cause of death, seven of the patients received an incorrect dose, Birchenough continued. In addition, the FDA highlighted 11 cases of serious liver injury, of which six patients were given an incorrect dose resulting in three of the 19 deaths."We believe that serious events in patients with mild or no baseline liver disease, treated with correct doses of OCALIVA, and the recommendation for increased monitoring could dramatically impact OCALIVA adoption in PBC, and introduces a potential overhang on the development for non alcoholic steatohepatitis (NASH), with phase 3 data not expected until early 2019 and potential increased risk of imbalance in serious adverse events (SAE's)," (9/21/2017)
  • 5. Cowen Inc analysts commented, "We hosted a group investor lunch recently with ICPT management." (6/12/2017)

Who are some of Intercept Pharmaceuticals' key competitors?

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the folowing people:

  • Paolo Fundaro, Independent Chairman of the Board (Age 43)
  • Mark Pruzanski M.D., President, Chief Executive Officer, Director (Age 49)
  • Sandip S. Kapadia, Chief Financial Officer, Treasurer (Age 47)
  • Lisa Bright, President, International (Age 49)
  • Jerome Benedict Durso, Chief Operating Officer (Age 49)
  • David A Ford, Chief Human Resource Officer
  • Richard Kim, Senior Vice President, Commercial U.S. (Age 48)
  • David M. Shapiro M.D., Chief Medical Officer (Age 62)
  • Srinivas Akkaraju M.D. Ph.D., Independent Director (Age 49)
  • Luca Benatti Ph.D., Independent Director (Age 56)

Who owns Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Senvest Management LLC (3.87%), First Trust Advisors LP (2.41%), Altrinsic Global Advisors LLC (1.24%), Pinnacle Associates Ltd. (0.86%), Sarissa Capital Management LP (0.73%) and Spark Investment Management LLC (0.72%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Institutional Ownership Trends for Intercept Pharmaceuticals.

Who sold Intercept Pharmaceuticals stock? Who is selling Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Guggenheim Capital LLC, QVT Financial LP, Kazazian Asset Management LLC, TIAA CREF Investment Management LLC, Schwab Charles Investment Management Inc., Bank of New York Mellon Corp and Geode Capital Management LLC. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Daniel G Welch, David Shapiro, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Insider Buying and Selling for Intercept Pharmaceuticals.

Who bought Intercept Pharmaceuticals stock? Who is buying Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Senvest Management LLC, First Trust Advisors LP, Pinnacle Associates Ltd., Sarissa Capital Management LP, Emerald Advisers Inc. PA, Peregrine Capital Management LLC, Two Sigma Investments LP and Altrinsic Global Advisors LLC. View Insider Buying and Selling for Intercept Pharmaceuticals.

How do I buy Intercept Pharmaceuticals stock?

Shares of Intercept Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of Intercept Pharmaceuticals stock can currently be purchased for approximately $59.13.

How big of a company is Intercept Pharmaceuticals?

Intercept Pharmaceuticals has a market capitalization of $1.54 billion and generates $130.96 million in revenue each year. The biopharmaceutical company earns $-360,370,000.00 in net income (profit) each year or ($14.39) on an earnings per share basis. Intercept Pharmaceuticals employs 456 workers across the globe.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]


MarketBeat Community Rating for Intercept Pharmaceuticals (ICPT)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  755 (Vote Outperform)
Underperform Votes:  390 (Vote Underperform)
Total Votes:  1,145
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Intercept Pharmaceuticals (NASDAQ:ICPT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.352.382.352.60
Ratings Breakdown: 3 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
9 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
9 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $128.37$138.75$143.53$215.00
Price Target Upside: 129.15% upside140.38% upside136.34% upside93.83% upside

Intercept Pharmaceuticals (NASDAQ:ICPT) Consensus Price Target History

Price Target History for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ:ICPT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/15/2018BMO Capital MarketsBoost Price TargetOutperform -> Outperform$152.00 -> $155.00HighView Rating Details
2/15/2018OppenheimerReiterated RatingHoldHighView Rating Details
2/14/2018Cantor FitzgeraldSet Price TargetHold$58.00HighView Rating Details
2/13/2018Wells Fargo & CoReiterated RatingMarket Perform$62.00 -> $57.00MediumView Rating Details
2/12/2018Deutsche BankInitiated CoverageBuy$103.00MediumView Rating Details
2/7/2018Goldman Sachs GroupDowngradeNeutral -> SellLowView Rating Details
1/25/2018Robert W. BairdReiterated RatingOutperform$332.00 -> $253.00LowView Rating Details
1/22/2018Credit Suisse GroupSet Price TargetBuy$201.00 -> $167.00HighView Rating Details
1/5/2018WedbushReiterated RatingBuy$253.00LowView Rating Details
12/29/2017CitigroupSet Price TargetHold$74.00HighView Rating Details
11/28/2017Leerink SwannReiterated RatingHold$60.00LowView Rating Details
11/1/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
11/1/2017CowenReiterated RatingBuy$112.00N/AView Rating Details
11/1/2017LaidlawUpgradeHold -> Buy$90.00N/AView Rating Details
10/13/2017Bank of AmericaLower Price TargetUnderperform$102.00 -> $73.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$136.00N/AView Rating Details
10/4/2017Royal Bank of CanadaReiterated RatingOutperform -> OutperformHighView Rating Details
10/4/2017JMP SecuritiesDowngradeOutperform -> Market PerformHighView Rating Details
9/26/2017Jefferies GroupReiterated RatingBuy$275.00 -> $135.00LowView Rating Details
9/22/2017Morgan StanleyReiterated RatingUnderweight$75.00 -> $50.00HighView Rating Details
2/16/2017FBR & CoReiterated RatingMarket Perform$200.00N/AView Rating Details
6/1/2016BarclaysReiterated RatingBuy$200.00 -> $205.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Intercept Pharmaceuticals (NASDAQ:ICPT) Earnings History and Estimates Chart

Earnings by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ ICPT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($3.38)N/AView Earnings Details
2/14/2018Q4 2017($3.39)($4.43)$39.01 million$37.69 millionViewN/AView Earnings Details
11/1/2017Q3 2017($3.48)($2.89)$36.95 million$41.33 millionViewN/AView Earnings Details
7/31/2017Q2 2017($3.62)($3.46)$27.50 million$30.89 millionViewN/AView Earnings Details
5/4/2017Q1 2017($4.27)($3.61)$15.88 million$21.00 millionViewListenView Earnings Details
2/23/2017Q416($3.74)($4.84)$8.96 million$13.00 millionViewN/AView Earnings Details
11/3/2016Q316($3.82)($3.59)$4.77 million$4.70 millionViewN/AView Earnings Details
8/4/2016Q216($3.69)($3.14)$1.72 million$5.52 millionViewN/AView Earnings Details
5/5/2016Q1($3.60)($3.33)$0.49 million$0.45 millionViewN/AView Earnings Details
2/23/2016Q415($3.15)($3.62)$0.43 million$0.45 millionViewListenView Earnings Details
11/9/2015Q315($2.74)($2.10)$0.42 million$0.45 millionViewN/AView Earnings Details
8/5/2015Q215($1.95)($1.99)$2.17 million$0.45 millionViewN/AView Earnings Details
5/11/2015Q115($1.75)($1.78)$1.70 million$1.70 millionViewListenView Earnings Details
3/2/2015Q414($1.53)($1.63)$0.42 million$0.04 millionViewN/AView Earnings Details
11/6/2014Q3($1.10)($1.69)$0.46 million$0.45 millionViewN/AView Earnings Details
8/11/2014Q214($1.10)$1.51$400.00 million$405.40 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.72)($1.59)$0.41 million$0.41 millionViewN/AView Earnings Details
3/14/2014Q4 13($0.70)($0.64)$0.41 million$0.41 millionViewN/AView Earnings Details
11/14/2013Q313($0.51)($1.65)$0.89 million$0.41 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.51)($0.79)$0.40 million$0.41 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.44)($0.62)$1.23 million$0.41 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.37)($0.43)ViewN/AView Earnings Details
11/26/2012Q3 2012($0.57)($1.86)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Intercept Pharmaceuticals (NASDAQ:ICPT) Earnings Estimates

2018 EPS Consensus Estimate: ($13.72)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($3.71)($3.24)($3.47)
Q2 20184($4.12)($3.06)($3.45)
Q3 20184($4.63)($2.57)($3.38)
Q4 20184($5.23)($2.09)($3.43)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Intercept Pharmaceuticals (NASDAQ:ICPT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Intercept Pharmaceuticals (NASDAQ ICPT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.50%
Institutional Ownership Percentage: 78.39%
Insider Trades by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ ICPT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/2/2017David ShapiroCMOSell349$58.90$20,556.10View SEC Filing  
10/2/2017Mark PruzanskiCEOSell1,532$58.87$90,188.84View SEC Filing  
10/2/2017Rachel McminnInsiderSell283$58.89$16,665.87View SEC Filing  
10/2/2017Richard J KimSVPSell48$58.10$2,788.80View SEC Filing  
10/2/2017Sandip KapadiaCFOSell354$58.83$20,825.82View SEC Filing  
9/1/2017David ShapiroCMOSell1,250$117.43$146,787.5045,812View SEC Filing  
8/25/2017Lisa BrightInsiderSell253$111.31$28,161.4323,324View SEC Filing  
8/2/2017Lisa BrightInsiderSell142$110.29$15,661.1823,477View SEC Filing  
8/1/2017David ShapiroCMOSell1,118$119.00$133,042.0045,680View SEC Filing  
7/31/2017Daniel G WelchDirectorSell602$123.93$74,605.863,108View SEC Filing  
7/31/2017Rachel McminnInsiderSell130$123.12$16,005.6017,158View SEC Filing  
7/20/2017Daniel G WelchDirectorSell217$126.76$27,506.923,710View SEC Filing  
7/14/2017Richard J KimSVPSell89$128.64$11,448.9611,253View SEC Filing  
7/11/2017David ShapiroCMOSell553$124.01$68,577.5344,562View SEC Filing  
7/3/2017David ShapiroCMOSell350$121.24$42,434.0045,215View SEC Filing  
7/3/2017Lisa BrightInsiderSell394$121.33$47,804.0223,619View SEC Filing  
7/3/2017Mark PruzanskiCEOSell1,434$121.78$174,632.52570,284View SEC Filing  
7/3/2017Richard J KimSVPSell50$121.69$6,084.5011,342View SEC Filing  
7/3/2017Sandip KapadiaCFOSell1,431$121.59$173,995.2920,569View SEC Filing  
6/26/2017Mark PruzanskiCEOSell40,000$130.80$5,232,000.00611,718View SEC Filing  
6/1/2017Lisa BrightInsiderSell698$110.73$77,289.5424,711View SEC Filing  
5/25/2017Lisa BrightInsiderSell254$117.52$29,850.0823,246View SEC Filing  
5/16/2017Lisa BrightInsiderSell113$119.74$13,530.6223,613View SEC Filing  
5/2/2017Lisa BrightInsiderSell426$114.00$48,564.0023,804View SEC Filing  
5/1/2017David ShapiroCMOSell1,117$112.18$125,305.0646,582View SEC Filing  
5/1/2017Rachel McminnInsiderSell114$113.12$12,895.6817,545View SEC Filing  
4/10/2017David ShapiroCMOSell558$108.51$60,548.5845,465View SEC Filing  
4/3/2017David ShapiroCMOSell346$115.00$39,790.0046,023View SEC Filing  
4/3/2017Lisa BrightInsiderSell389$115.00$44,735.0022,925View SEC Filing  
4/3/2017Mark PruzanskiCEOSell1$115.00$115.00571,718View SEC Filing  
2/27/2017Lisa BrightInsiderSell254$119.48$30,347.9221,695View SEC Filing  
1/31/2017Lisa BrightInsiderSell134$108.96$14,600.6417,383View SEC Filing  
1/9/2017David ShapiroCMOSell1,565$106.01$165,905.6540,369View SEC Filing  
1/3/2017David ShapiroCMOSell988$103.92$102,672.9641,934View SEC Filing  
1/3/2017Mark PruzanskiCEOSell2,802$103.92$291,183.84552,705View SEC Filing  
1/3/2017Rachel McminnInsiderSell816$103.92$84,798.7212,916View SEC Filing  
12/2/2016David ShapiroCMOSell1,350$99.75$134,662.5042,922View SEC Filing  
11/25/2016Lisa BrightInsiderSell249$113.60$28,286.4018,209View SEC Filing  
10/31/2016Rachel McminnInsiderSell129$123.82$15,972.7813,732View SEC Filing  
10/10/2016David ShapiroCMOSell411$153.34$63,022.7444,272View SEC Filing  
10/3/2016Barbara Gayle DuncanCAOSell147$163.20$23,990.4030,661View SEC Filing  
10/3/2016David ShapiroCMOSell1,513$163.08$246,740.0446,196View SEC Filing  
10/3/2016Lisa BrightInsiderSell155$163.20$25,296.0018,305View SEC Filing  
10/3/2016Mark PruzanskiCEOSell705$163.20$115,056.00552,020View SEC Filing  
9/26/2016David ShapiroCMOSell3,545$165.08$585,208.6045,732View SEC Filing  
9/20/2016Mark PruzanskiCEOSell35,000$165.00$5,775,000.00579,314View SEC Filing  
8/25/2016Lisa BrightInsiderSell246$159.00$39,114.0018,460View SEC Filing  
8/1/2016Rachel McminnInsiderSell125$176.57$22,071.2513,861View SEC Filing  
7/5/2016Barbara Gayle DuncanCAOSell146$145.11$21,186.06View SEC Filing  
7/5/2016David ShapiroCMOSell163$145.11$23,652.93View SEC Filing  
7/5/2016Lisa BrightInsiderSell155$145.11$22,492.05View SEC Filing  
7/5/2016Mark PruzanskiCEOSell714$145.11$103,608.54View SEC Filing  
5/25/2016Lisa BrightInsiderSell251$137.50$34,512.5018,855View SEC Filing  
5/2/2016Rachel McminnInsiderSell130$147.49$19,173.7014,087View SEC Filing  
4/4/2016Barbara Gayle DuncanCFOSell144$130.76$18,829.4430,948View SEC Filing  
4/4/2016David ShapiroCMOSell165$130.76$21,575.4048,546View SEC Filing  
4/4/2016Lisa BrightInsiderSell153$130.76$20,006.2819,106View SEC Filing  
4/4/2016Mark PruzanskiCEOSell708$130.76$92,578.08548,248View SEC Filing  
2/25/2016Lisa BrightInsiderSell241$115.22$27,768.0219,259View SEC Filing  
2/1/2016Rachel McminnInsiderSell128$103.56$13,255.687,621View SEC Filing  
1/13/2016Lisa BrightinsiderSell728$125.52$91,378.5611,700View SEC Filing  
1/4/2016Barbara Gayle DuncanCFOSell468$145.90$68,281.2024,892View SEC Filing  
1/4/2016David ShapiroCMOSell533$145.90$77,764.7040,911View SEC Filing  
1/4/2016Mark PruzanskiCEOSell2,126$145.90$310,183.40529,556View SEC Filing  
1/4/2016Rachel McminnInsiderSell469$145.90$68,427.107,749View SEC Filing  
11/25/2015Lisa BrightInsiderSell1,150$182.96$210,404.0012,428View SEC Filing  
11/16/2015David ShapiroCMOSell4,264$178.53$761,251.9228,395View SEC Filing  
11/10/2015David ShapiroCMOSell3,500$204.15$714,525.0029,159View SEC Filing  
11/10/2015Klaus R. Dr VeitingerDirectorSell1,000$198.25$198,250.002,166View SEC Filing  
11/2/2015Rachel McminnInsiderSell125$160.24$20,030.008,218View SEC Filing  
10/2/2015Barbara Gayle DuncanCFOSell1,054$163.17$171,981.1824,062View SEC Filing  
10/2/2015David ShapiroCMOSell1,140$160.12$182,536.8029,159View SEC Filing  
9/21/2015Nicole WilliamsDirectorSell973$194.82$189,559.86962View SEC Filing  
9/15/2015David ShapiroCMOSell3,500$191.28$669,480.0023,527View SEC Filing  
8/17/2015David ShapiroCMOSell4,272$209.37$894,428.64View SEC Filing  
7/20/2015Nicole WilliamsDirectorSell973$279.01$271,476.73View SEC Filing  
7/10/2015Mark PruzanskiCEOSell12,500$250.00$3,125,000.00View SEC Filing  
7/6/2015Luciano AdoriniInsiderSell4,067$579.93$2,358,575.31View SEC Filing  
7/1/2015Barbara Gayle DuncanCFOSell1,000$242.10$242,100.00View SEC Filing  
7/1/2015David ShapiroCMOSell3,781$238.66$902,373.46View SEC Filing  
6/22/2015Nicole WilliamsDirectorSell974$265.14$258,246.36View SEC Filing  
6/15/2015David ShapiroCMOSell3,500$241.58$845,530.00View SEC Filing  
6/8/2015Luciano AdoriniInsiderSell4,000$248.40$993,600.00View SEC Filing  
5/11/2015Klaus R Dr VeitingerDirectorSell391$279.07$109,116.37View SEC Filing  
5/6/2015Luciano AdoriniInsiderSell4,000$259.97$1,039,880.00View SEC Filing  
4/20/2015Nicole WilliamsDirectorSell974$278.50$271,259.00View SEC Filing  
4/6/2015Luciano AdoriniInsiderSell4,000$269.64$1,078,560.00View SEC Filing  
4/2/2015David ShapiroCMOSell3,459$275.25$952,089.75View SEC Filing  
3/26/2015Orbimed Advisors LlcDirectorSell157,200$286.75$45,077,100.00View SEC Filing  
3/25/2015Orbimed Advisors LlcDirectorSell207,800$274.41$57,022,398.00View SEC Filing  
3/24/2015Jonathan SilversteinDirectorSell45,600$272.00$12,403,200.00View SEC Filing  
3/23/2015Jonathan SilversteinDirectorSell159,400$275.18$43,863,692.00View SEC Filing  
3/16/2015David ShapiroCMOSell3,500$286.90$1,004,150.00View SEC Filing  
1/12/2015Klaus R Dr VeitingerDirectorSell233$150.01$34,952.33View SEC Filing  
1/5/2015Barbara Gayle DuncanCFOSell141$176.49$24,885.09View SEC Filing  
1/5/2015Daniel Paul ReganInsiderSell146$176.49$25,767.54View SEC Filing  
1/5/2015David ShapiroCMOSell664$172.63$114,626.32View SEC Filing  
1/5/2015Mark PruzanskiCEOSell461$176.49$81,361.89View SEC Filing  
1/2/2015Barbara Gayle DuncanCFOSell1,000$156.40$156,400.00View SEC Filing  
11/17/2014David ShapiroCMOSell4,790$158.82$760,747.80View SEC Filing  
11/12/2014Srinivas AkkarajuDirectorBuy2,000$167.19$334,380.00View SEC Filing  
11/10/2014Klaus R Dr VeitingerDirectorSell233$175.95$40,996.35View SEC Filing  
11/3/2014Mark PruzanskiCEOSell10,000$259.41$2,594,100.00View SEC Filing  
10/10/2014Klaus R Dr VeitingerDirectorSell391$223.65$87,447.15View SEC Filing  
10/2/2014David ShapiroCMOSell5,020$231.63$1,162,782.60View SEC Filing  
10/1/2014Barbara Gayle DuncanCFOSell1,000$233.12$233,120.00View SEC Filing  
10/1/2014David ShapiroCMOSell4,188$231.17$968,139.96View SEC Filing  
10/1/2014Mark PruzanskiCEOSell10,000$228.82$2,288,200.00View SEC Filing  
9/15/2014David ShapiroCMOSell4,000$281.19$1,124,760.00View SEC Filing  
9/10/2014Klaus R Dr VeitingerDirectorSell391$280.50$109,675.50View SEC Filing  
9/2/2014Mark PruzanskiCEOSell10,000$286.49$2,864,900.00View SEC Filing  
8/27/2014David ShapiroCMOSell10,000$293.93$2,939,300.00View SEC Filing  
8/26/2014Orbimed Advisors LlcDirectorSell111,258$298.06$33,161,559.48View SEC Filing  
8/25/2014Jonathan SilversteinDirectorSell50,000$295.59$14,779,500.00View SEC Filing  
8/15/2014David ShapiroCMOSell4,774$291.49$1,391,573.26View SEC Filing  
8/12/2014Daniel Paul ReganInsiderSell8,124$325.70$2,645,986.80View SEC Filing  
8/12/2014Klaus R Dr VeitingerDirectorSell316$345.62$109,215.92View SEC Filing  
8/1/2014Mark PruzanskiCEOSell10,000$226.72$2,267,200.00View SEC Filing  
7/10/2014Klaus R Dr VeitingerDirectorSell391$219.15$85,687.65View SEC Filing  
7/7/2014Lorenzo TallarigoDirectorSell2,000$243.06$486,120.00View SEC Filing  
7/2/2014David ShapiroCMOSell5,036$244.73$1,232,460.28View SEC Filing  
7/1/2014Mark PruzanskiCEOSell10,000$250.61$2,506,100.00View SEC Filing  
6/16/2014David ShapiroCMOSell4,000$278.15$1,112,600.00View SEC Filing  
6/2/2014Mark PruzanskiCEOSell10,000$230.60$2,306,000.00View SEC Filing  
5/9/2014Lorenzo TallarigoDirectorSell2,007$254.68$511,142.76View SEC Filing  
5/1/2014Mark PruzanskiCEOSell10,000$263.17$2,631,700.00470,174View SEC Filing  
4/16/2014Mark PruzanskiCEOSell10,000$242.22$2,422,200.00470,174View SEC Filing  
4/14/2014Barbara Gayle DuncanCFOSell1,154$279.00$321,966.0013,510View SEC Filing  
4/10/2014Lorenzo TallarigoDirectorSell349,318$317.71$110,981,821.781,640View SEC Filing  
4/9/2014Orbimed Advisors LlcDirectorSell81,305$320.00$26,017,600.00View SEC Filing  
4/7/2014Luciano AdoriniInsiderSell2,000$283.90$567,800.007,041View SEC Filing  
4/2/2014David ShapiroCMOSell5,393$331.83$1,789,559.1913,679View SEC Filing  
3/17/2014David ShapiroCMOSell4,456$437.49$1,949,455.4413,124View SEC Filing  
2/14/2014Paolo FundaroDirectorSell7,246$375.26$2,719,133.961,655View SEC Filing  
1/16/2014Mark PruzanskiCEOSell10,000$273.68$2,736,800.00430,298View SEC Filing  
1/16/2014Srinivas AkkarajuDirectorSell3,250$267.94$870,805.001,943View SEC Filing  
1/8/2014David ShapiroCMOSell4,928$71.85$354,076.808,663View SEC Filing  
1/7/2014Lorenzo TallarigoDirectorSell1,839$67.41$123,966.991,640View SEC Filing  
1/7/2014Luciano AdoriniInsiderSell1,634$67.41$110,147.946,392View SEC Filing  
12/16/2013David ShapiroCMOSell5,016$62.11$311,543.763,000View SEC Filing  
10/21/2013Francesco MicheliMajor ShareholderSell124,912$62.50$7,807,000.00View SEC Filing  
10/21/2013Jonathan SilversteinDirectorSell40,088$62.50$2,505,500.00View SEC Filing  
10/21/2013Luciano AdoriniInsiderSell2,000$55.51$111,020.00View SEC Filing  
10/15/2013Francesco MicheliMajor ShareholderSell1,123,415$62.50$70,213,437.50View SEC Filing  
10/15/2013Orbimed Advisors LlcDirectorSell376,585$62.50$23,536,562.50View SEC Filing  
10/2/2013David ShapiroCMOSell4,392$72.80$319,737.60View SEC Filing  
9/20/2013Luciano AdoriniInsiderSell2,000$61.07$122,140.005,094View SEC Filing  
9/17/2013Mark PruzanskiCEOSell25,000$52.00$1,300,000.00402,032View SEC Filing  
9/13/2013Mark PruzanskiCEOSell12,500$49.02$612,750.00402,032View SEC Filing  
8/20/2013Luciano AdoriniInsiderSell2,000$44.18$88,360.005,094View SEC Filing  
8/16/2013David ShapiroCMOSell5,016$49.20$246,787.204,266View SEC Filing  
8/15/2013David ShapiroCMOSell4,754$45.04$214,120.162,532View SEC Filing  
8/12/2013Mark PruzanskiCEOSell12,500$45.98$574,750.00402,032View SEC Filing  
8/12/2013Paolo FundaroDirectorSell4,759$46.13$219,532.671,330View SEC Filing  
7/22/2013Luciano AdoriniInsiderSell2,000$49.44$98,880.00View SEC Filing  
7/15/2013Mark PruzanskiCEOSell25,000$50.05$1,251,250.00View SEC Filing  
7/9/2013Mark PruzanskiCEOSell37,500$46.36$1,738,500.00View SEC Filing  
7/8/2013Barbara Gayle DuncanCFOSell25,000$45.39$1,134,750.00View SEC Filing  
7/2/2013David ShapiroCMOSell4,369$43.63$190,619.47View SEC Filing  
6/26/2013Mark PruzanskiCEOSell12,500$40.06$500,750.00View SEC Filing  
6/20/2013Luciano AdoriniInsiderSell2,000$37.07$74,140.00View SEC Filing  
6/20/2013Mark PruzanskiCEOSell25,000$38.25$956,250.00View SEC Filing  
6/19/2013Barbara Gayle DuncanCFOSell50,575$34.50$1,744,837.50View SEC Filing  
6/17/2013David ShapiroCMOSell5,016$32.72$164,123.52View SEC Filing  
5/28/2013Barbara Gayle DuncanCFOSell6,225$34.50$214,762.50View SEC Filing  
5/20/2013Barbara Gayle DuncanCFOSell28,200$34.50$972,900.00View SEC Filing  
5/16/2013David ShapiroCMOSell5,016$31.31$157,050.96View SEC Filing  
4/9/2013David ShapiroCMOSell3,750$34.41$129,037.50View SEC Filing  
10/16/2012Jonathan SilversteinDirectorBuy333,334$15.00$5,000,010.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Intercept Pharmaceuticals (NASDAQ ICPT) News Headlines

Source:
DateHeadline
Intercept Pharmaceuticals (ICPT) Upgraded to Hold by Zacks Investment ResearchIntercept Pharmaceuticals (ICPT) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - February 19 at 1:08 PM
Cantor Fitzgerald Comments on Intercept Pharmaceuticals Incs FY2018 Earnings (ICPT)Cantor Fitzgerald Comments on Intercept Pharmaceuticals Inc's FY2018 Earnings (ICPT)
www.americanbankingnews.com - February 19 at 5:58 AM
Q1 2018 Earnings Forecast for Intercept Pharmaceuticals Inc (ICPT) Issued By Jefferies GroupQ1 2018 Earnings Forecast for Intercept Pharmaceuticals Inc (ICPT) Issued By Jefferies Group
www.americanbankingnews.com - February 19 at 2:20 AM
Q1 2018 EPS Estimates for Intercept Pharmaceuticals Inc (ICPT) Decreased by AnalystQ1 2018 EPS Estimates for Intercept Pharmaceuticals Inc (ICPT) Decreased by Analyst
www.americanbankingnews.com - February 19 at 2:20 AM
Wells Fargo & Co Reiterates "Market Perform" Rating for Intercept Pharmaceuticals (ICPT)Wells Fargo & Co Reiterates "Market Perform" Rating for Intercept Pharmaceuticals (ICPT)
www.americanbankingnews.com - February 18 at 7:00 PM
Intercept Pharmaceuticals: What The Latest Earnings Foretell ... - Seeking AlphaIntercept Pharmaceuticals: What The Latest Earnings Foretell ... - Seeking Alpha
seekingalpha.com - February 18 at 8:34 AM
$40.35 Million in Sales Expected for Intercept Pharmaceuticals Inc (ICPT) This Quarter$40.35 Million in Sales Expected for Intercept Pharmaceuticals Inc (ICPT) This Quarter
www.americanbankingnews.com - February 18 at 2:24 AM
Intercept Pharmaceuticals (ICPT) Hold Rating Reiterated at OppenheimerIntercept Pharmaceuticals' (ICPT) Hold Rating Reiterated at Oppenheimer
www.americanbankingnews.com - February 17 at 7:40 PM
Intercept Pharmaceuticals (ICPT) Upgraded at BidaskClubIntercept Pharmaceuticals (ICPT) Upgraded at BidaskClub
www.americanbankingnews.com - February 17 at 12:26 PM
Intercept Pharmaceuticals (ICPT) PT Raised to $155.00Intercept Pharmaceuticals (ICPT) PT Raised to $155.00
www.americanbankingnews.com - February 15 at 1:43 PM
Intercept Pharmaceuticals Inc (ICPT) Forecasted to Earn FY2017 Earnings of ($13.17) Per ShareIntercept Pharmaceuticals Inc (ICPT) Forecasted to Earn FY2017 Earnings of ($13.17) Per Share
www.americanbankingnews.com - February 15 at 7:56 AM
Cantor Fitzgerald Analysts Give Intercept Pharmaceuticals (ICPT) a $58.00 Price TargetCantor Fitzgerald Analysts Give Intercept Pharmaceuticals (ICPT) a $58.00 Price Target
www.americanbankingnews.com - February 14 at 1:38 PM
Intercept Pharmaceuticals Reports Full Year and Fourth Quarter 2017 Financial Results and Provides Business UpdateIntercept Pharmaceuticals Reports Full Year and Fourth Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - February 14 at 9:37 AM
Intercept (ICPT) Misses on Q4 Earnings & SalesIntercept (ICPT) Misses on Q4 Earnings & Sales
finance.yahoo.com - February 14 at 9:37 AM
Is Intercept Pharmaceuticals Inc’s (NASDAQ:ICPT) CEO Incentives Align With Yours?Is Intercept Pharmaceuticals Inc’s (NASDAQ:ICPT) CEO Incentives Align With Yours?
finance.yahoo.com - February 14 at 9:37 AM
Intercept Pharmaceuticals (ICPT) Releases  Earnings Results, Misses Expectations By $1.04 EPSIntercept Pharmaceuticals (ICPT) Releases Earnings Results, Misses Expectations By $1.04 EPS
www.americanbankingnews.com - February 14 at 9:04 AM
Intercept Pharmaceuticals (ICPT) Scheduled to Post Quarterly Earnings on WednesdayIntercept Pharmaceuticals (ICPT) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 14 at 2:20 AM
Intercept Starts OCA Trial for NASH Patients With CirrhosisIntercept Starts OCA Trial for NASH Patients With Cirrhosis
finance.yahoo.com - February 13 at 9:44 AM
Intercept Pharma (ICPT) Announces Phase 3 REVERSE Trial Evaluating OCA for Treatment of NASH Patients with Compensated CirrhosisIntercept Pharma (ICPT) Announces Phase 3 REVERSE Trial Evaluating OCA for Treatment of NASH Patients with Compensated Cirrhosis
www.streetinsider.com - February 12 at 4:01 PM
Intercept Pharmaceuticals (ICPT) Now Covered by Deutsche BankIntercept Pharmaceuticals (ICPT) Now Covered by Deutsche Bank
www.americanbankingnews.com - February 12 at 1:32 PM
Will Ocaliva Sales Dampen Intercepts (ICPT) Q4 Earnings?Will Ocaliva Sales Dampen Intercept's (ICPT) Q4 Earnings?
finance.yahoo.com - February 12 at 9:36 AM
Will Ocaliva Sales Dampen Intercept's (ICPT) Q4 Earnings?Will Ocaliva Sales Dampen Intercept's (ICPT) Q4 Earnings?
finance.yahoo.com - February 12 at 9:36 AM
Intercept Pharmaceuticals Inc (ICPT) Receives Consensus Rating of "Hold" from AnalystsIntercept Pharmaceuticals Inc (ICPT) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 9 at 8:30 AM
Intercept to Report 2017 Full Year Financial Results on February 14 and Present at Upcoming ConferencesIntercept to Report 2017 Full Year Financial Results on February 14 and Present at Upcoming Conferences
finance.yahoo.com - February 8 at 8:28 AM
FY2021 EPS Estimates for Intercept Pharmaceuticals Inc Lifted by Analyst (ICPT)FY2021 EPS Estimates for Intercept Pharmaceuticals Inc Lifted by Analyst (ICPT)
www.americanbankingnews.com - February 5 at 9:18 AM
Head-To-Head Survey: Intercept Pharmaceuticals (ICPT) vs. Its CompetitorsHead-To-Head Survey: Intercept Pharmaceuticals (ICPT) vs. Its Competitors
www.americanbankingnews.com - February 4 at 5:16 AM
Intercept Pharma (ICPT) Confirms US Prescribing Information for Ocaliva to Reinforce Appropriate Dosing in PBC ... - StreetInsider.comIntercept Pharma (ICPT) Confirms US Prescribing Information for Ocaliva to Reinforce Appropriate Dosing in PBC ... - StreetInsider.com
www.streetinsider.com - February 2 at 4:05 PM
Healthcare Industry Trends And Its Impact On Intercept Pharmaceuticals Inc (NASDAQ:ICPT)Healthcare Industry Trends And Its Impact On Intercept Pharmaceuticals Inc (NASDAQ:ICPT)
finance.yahoo.com - February 2 at 4:05 PM
FY2017 EPS Estimates for Intercept Pharmaceuticals Inc (ICPT) Lifted by OppenheimerFY2017 EPS Estimates for Intercept Pharmaceuticals Inc (ICPT) Lifted by Oppenheimer
www.americanbankingnews.com - February 1 at 6:40 AM
Intercept Pharmaceuticals Inc (ICPT) Expected to Post Quarterly Sales of $40.81 MillionIntercept Pharmaceuticals Inc (ICPT) Expected to Post Quarterly Sales of $40.81 Million
www.americanbankingnews.com - February 1 at 3:00 AM
Intercept Pharmaceuticals Inc (ICPT) Expected to Post Q2 2018 Earnings of ($3.09) Per ShareIntercept Pharmaceuticals Inc (ICPT) Expected to Post Q2 2018 Earnings of ($3.09) Per Share
www.americanbankingnews.com - January 31 at 9:58 AM
 Brokerages Anticipate Intercept Pharmaceuticals Inc (ICPT) Will Post Earnings of -$3.47 Per Share Brokerages Anticipate Intercept Pharmaceuticals Inc (ICPT) Will Post Earnings of -$3.47 Per Share
www.americanbankingnews.com - January 30 at 7:10 PM
Intercept Pharmaceuticals (ICPT) Receives "Hold" Rating from OppenheimerIntercept Pharmaceuticals (ICPT) Receives "Hold" Rating from Oppenheimer
www.americanbankingnews.com - January 30 at 9:52 AM
Wedbush Weighs in on Intercept Pharmaceuticals Incs FY2022 Earnings (ICPT)Wedbush Weighs in on Intercept Pharmaceuticals Inc's FY2022 Earnings (ICPT)
www.americanbankingnews.com - January 29 at 9:10 AM
BidaskClub Upgrades Intercept Pharmaceuticals (ICPT) to "Sell"BidaskClub Upgrades Intercept Pharmaceuticals (ICPT) to "Sell"
www.americanbankingnews.com - January 28 at 8:54 AM
Intercept Pharmaceuticals (ICPT) Stock Rating Reaffirmed by Robert W. BairdIntercept Pharmaceuticals (ICPT) Stock Rating Reaffirmed by Robert W. Baird
www.americanbankingnews.com - January 25 at 8:00 PM
Credit Suisse Group Reaffirms "Outperform" Rating for Intercept Pharmaceuticals (ICPT)Credit Suisse Group Reaffirms "Outperform" Rating for Intercept Pharmaceuticals (ICPT)
www.americanbankingnews.com - January 22 at 9:52 AM
What Does Intercept Pharmaceuticals Inc’s (NASDAQ:ICPT) Ownership Structure Look Like?What Does Intercept Pharmaceuticals Inc’s (NASDAQ:ICPT) Ownership Structure Look Like?
finance.yahoo.com - January 17 at 11:47 AM
Intercept Pharmaceuticals (ICPT) Upgraded to "Hold" at Zacks Investment ResearchIntercept Pharmaceuticals (ICPT) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 16 at 11:52 AM
Intercept Pharmaceuticals Inc (ICPT) Given Consensus Recommendation of "Hold" by BrokeragesIntercept Pharmaceuticals Inc (ICPT) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 15 at 7:42 AM
The Primary Reason Intercept Pharmaceuticals, Inc. Was Nearly Halved in 2017The Primary Reason Intercept Pharmaceuticals, Inc. Was Nearly Halved in 2017
finance.yahoo.com - January 12 at 3:12 PM
5 Top Stocks for January5 Top Stocks for January
finance.yahoo.com - January 12 at 5:24 AM
Wedbush Reaffirms Buy Rating for Intercept Pharmaceuticals (ICPT)Wedbush Reaffirms Buy Rating for Intercept Pharmaceuticals (ICPT)
www.americanbankingnews.com - January 5 at 4:22 PM
4 Biotech Stocks to Buy for 2018 With Up to 100% Upside Potential4 Biotech Stocks to Buy for 2018 With Up to 100% Upside Potential
247wallst.com - January 2 at 3:11 PM
Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : January 1, 2018Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : January 1, 2018
finance.yahoo.com - January 1 at 3:15 PM
$43.35 Million in Sales Expected for Intercept Pharmaceuticals Inc (ICPT) This Quarter$43.35 Million in Sales Expected for Intercept Pharmaceuticals Inc (ICPT) This Quarter
www.americanbankingnews.com - December 30 at 4:34 PM
Intercept - Concerns Remain Going Into 2018 - Seeking Alpha - Seeking AlphaIntercept - Concerns Remain Going Into 2018 - Seeking Alpha - Seeking Alpha
seekingalpha.com - December 30 at 5:32 AM
Intercept Pharmaceuticals (ICPT) Given a $74.00 Price Target by Citigroup AnalystsIntercept Pharmaceuticals (ICPT) Given a $74.00 Price Target by Citigroup Analysts
www.americanbankingnews.com - December 29 at 7:20 AM
This Biotech Stock Just Pushed Back A Key Trial Until Early 2018This Biotech Stock Just Pushed Back A Key Trial Until Early 2018
finance.yahoo.com - December 28 at 3:00 PM
What Should Investors Know About Intercept Pharmaceuticals Inc’s (NASDAQ:ICPT) Long Term Outlook?What Should Investors Know About Intercept Pharmaceuticals Inc’s (NASDAQ:ICPT) Long Term Outlook?
finance.yahoo.com - December 27 at 2:28 PM

SEC Filings

Intercept Pharmaceuticals (NASDAQ:ICPT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Intercept Pharmaceuticals (NASDAQ:ICPT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Intercept Pharmaceuticals (NASDAQ ICPT) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.